Aptorum Group Ltd
aptorumgroup.comWhat Do They Do?
Develops drug candidates and diagnostic technologies aimed at treating and diagnosing diseases.
20-F for FY2025, filed Mar 27, 2026The Company now focuses all of its efforts on R&D and therefore no longer performs any therapeutic services. While the Company may commence…View ↗
Our industry is highly competitive and subject to rapid and significant change. While we believe that our development and commercialization…View ↗
The technologies underlying our various research and development projects are the subject of various patents and patent applications…View ↗
How Do They Make Money?
Revenue came from healthcare consultations and medical treatment for patients in Hong Kong; each service was completed in a visit generally lasting less than a day.
20-F for FY2025, filed Mar 27, 2026Revenues are derived from healthcare services rendered to patients for healthcare consultation and medical treatment. Revenue is reported…View ↗
The Group recognizes revenue as its performance obligations are completed. Healthcare services are treated as a single performance…View ↗
For the year ended December 31, 2023, all revenue came from provision of healthcare services in Hong Kong.View ↗
$431.4K
-
20-F for FY2025, filed Mar 27, 2026
$431.4K ↗
Who Are Their Customers?
The group’s clinic served patients in Hong Kong with healthcare consultations and medical treatment; clinic services have since ended.
20-F for FY2025, filed Mar 27, 2026Revenues are derived from healthcare services rendered to patients for healthcare consultation and medical treatment. Revenue is reported…View ↗
During the second quarter of 2023, the Group made a decision to streamline its operations by terminating clinic services and suspending…View ↗
For the year ended December 31, 2023, all revenue came from provision of healthcare services in Hong Kong.View ↗
Do Revenues Turn Into Profits?
No. It lost $2.8M in FY2023.
20-F for FY2025, filed Mar 27, 2026
−$2.8MView ↗
20-F for FY2025, filed Mar 27, 2026
−$7.7MView ↗
How Are They Changing?
-
Sep 4, 2026
Ian Huen became Niki BioSolutions’ CEO
He took the role in connection with the merger; Alidad Mireskandari became COO.
Sources
8-K, filed Sep 4, 2026
In connection with the previously announced merger transaction, Mr. Ian Huen and Alidad Mireskandari became the CEO and COO, respectively…View ↗
-
Jul 20, 2026
DiamiR merger closed, making it a wholly owned subsidiary
Aptorum became a Delaware corporation and changed its name to Niki BioSolutions.
Sources
8-K, filed Jul 20, 2026
On July 20, 2026 (the “Closing Date”), after obtaining the requisite shareholder approval and satisfying the closing conditions, Aptorum…View ↗
From broader operations to R&D
The older report described therapeutic and non-therapeutic segments, including natural supplements, diagnostics projects and an outpatient clinic. The latest says all efforts are focused on R&D and therapeutic services have ended.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Mar 27, 2026The Company now focuses all of its efforts on R&D and therefore no longer performs any therapeutic services. While the Company may commence…View ↗
Loading...
